Immunohistochemical and quantitative competitive PCR analyses of midkine and pleiotrophin expression in cervical cancer

Moon, Hye Sung; Park, Won I.; Sung, Sun Hee; Choi, Eun A; Chung, Hye Won; Woo, Bock Hi

doi:10.1016/s0090-8258(02)00070-7

Cited by 35 publications

(36 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…To explore the possible correlation between MK expression and tumour progression, we examined MK Figure 2A). These findings suggest a possible involvement of MK in pathogenesis and progression of pancreatic head carcinoma, as previously suggested for other carcinomas (Aridome et al, 1995;O'Brien et al, 1996;Moon et al, 2003). Using 75 pancreatic head carcinomas, we investigated immunohistochemically whether MK expression was associated with clinicopathologic factors including prognosis.…”

Section: Discussionsupporting

confidence: 69%

“…Ten fields were randomly selected, and expression in 1000 tumour cells (100 cells per field) was evaluated with high-power ( Â 200) microscopy. First, we classified the specimens stained by anti-MK antibody with a visual grading system employed for immunohistochemical evaluation (Moon et al, 2003). Samples were considered negative if less than 10% of the cells are stained for MK; weak was defined as 10 -25% of the tumour staining positive; moderate as 25 -50% staining, and strong as more than 50% of the tumour staining positive.…”

Section: Immunohistochemical Stainingmentioning

confidence: 99%

See 1 more Smart Citation

Clinical significance of midkine expression in pancreatic head carcinoma

et al. 2007

View full text Add to dashboard Cite

Midkine (MK) is a heparin-binding growth factor and a product of a retinoic acid-responsive gene. Midkine is overexpressed in many carcinomas and thought to play an important role in carcinogenesis. However, no studies have been focussed on the role of MK in pancreatic carcinoma. This study sought to evaluate the clinical significance of MK expression in pancreatic head carcinoma, including the relationship between immunohistochemical expression and clinicopathologic factors such as prognosis. Immunohistochemical expression of MK and CD34 was evaluated in pancreatic head carcinoma specimens from 75 patients who underwent surgical resection. Midkine was expressed in 53.3% of patients. Midkine expression was significantly correlated with venous invasion, microvessel density, and liver metastasis (P ¼ 0.0063, 0.0025, and 0.0153, respectively). The 5-year survival rate was significantly lower for patients positive for MK vs patients negative for MK (P ¼ 0.0073). Multivariate analysis revealed that MK expression was an independent prognostic factor (P ¼ 0.0033). This is the first report of an association between MK expression and pancreatic head carcinoma. Midkine may play an important role in the progression of pancreatic head carcinoma, and evaluation of MK expression is useful for predicting malignant properties of pancreatic head carcinoma.

show abstract

Section: Discussionsupporting

confidence: 69%

Section: Immunohistochemical Stainingmentioning

confidence: 99%

Clinical significance of midkine expression in pancreatic head carcinoma

et al. 2007

View full text Add to dashboard Cite

show abstract

“…In the past few decades, there was more evidence indicating the overexpression of midkine in tumor tissues or serum of cancer patients, such as oral squamous cell carcinoma [11], gastrointestinal cancer [12], colorectal cancer [13], hepatobiliary carcinoma [14], intrahepatic cholangiocarcinoma [15], lung cancer [16], thyroid papillary carcinoma [17], lymphoblastic leukemia [18], cervical cancer [19], ovarian cancer [20], and prostate cancer [21].…”

Section: Discussionmentioning

confidence: 99%

“…Midkine plays critical roles in tumor development and progression through regulating cell proliferation [6], cell motility [7], cell survival [8], angiogenesis [9], and transformation of fibroblasts [10]. The messenger RNA (mRNA) and protein levels of midkine expression have also been found to be elevated in a variety of human cancers such as oral squamous cell carcinoma [11], gastrointestinal cancer [12], colorectal cancer [13], hepatobiliary carcinoma [14], intrahepatic cholangiocarcinoma [15], lung cancer [16], thyroid papillary carcinoma [17], lymphoblastic leukemia [18], cervical cancer [19], ovarian cancer [20], and prostate cancer [21]. However, the clinical significance of midkine protein expression in breast cancer patients remains unknown.…”

Section: Introductionmentioning

confidence: 99%

The clinical and prognostic significance of midkine in breast cancer patients

Tian

Zhang

et al. 2015

Tumor Biol.

View full text Add to dashboard Cite

Midkine overexpression has been shown to be a tumor biomarker in several types of human cancer, but little is known about the clinical significance of midkine in breast cancer patients. The aim of this study was to analyze the expression of midkine in breast cancer and its correlation with clinicopathological characteristics, including breast cancer patient's survival. The expression status of midkine in breast cancer from Gene Expression Omnibus (GEO accession number: GDS3853) was observed initially. Furthermore, the expression of midkine messenger RNA (mRNA) and protein was examined in breast cancer and normal mammary tissues through real-time PCR and immunohistochemistry. Moreover, the relationship of midkine protein expression with clinical characteristics of 170 breast cancer patients was analyzed by immunohistochemistry. In our results, midkine was up-expressed in breast cancer tissues compared with normal mammary tissues in microarray data (GDS3853). Midkine mRNA and protein expression was significantly increased in breast cancer tissues than in normal mammary tissues. By immunohistochemistry, high levels of midkine protein were positively associated with the status of clinical stage, T classification, N classification, and M classification in breast cancer patients. Furthermore, midkine overexpression was an independent poor prognostic indicator for the survival of patients with breast cancer. In conclusion, overexpression of midkine protein serves as an unfavorable prognostic biomarker in breast cancer patients.

show abstract

“…Two investigators, who were unaware of the clinical information, examined all the stains independently. Midkine immunostaining was semi-quantified with a visual grading system in which the staining intensity was categorized as negative, weak, moderate or strong, similar to a previously reported system 9 . Samples were considered negative if less than 5% of the cells stained for midkine; weak was defined as <25% of the tumour staining positive; moderate as 25%-50% of the tumour staining positive and strong as >50% of the tumour staining positive.…”

Section: Evaluation Of Immunostainingmentioning

confidence: 99%

Evaluation of expression of midkine in oral squamous cell carcinoma and its correlation with tumour angiogenesis

Ruan

et al. 2007

International Journal of Oral and Maxillofacial Surgery

View full text Add to dashboard Cite

Immunohistochemical and quantitative competitive PCR analyses of midkine and pleiotrophin expression in cervical cancer

Cited by 35 publications

References 23 publications

Clinical significance of midkine expression in pancreatic head carcinoma

Clinical significance of midkine expression in pancreatic head carcinoma

The clinical and prognostic significance of midkine in breast cancer patients

Evaluation of expression of midkine in oral squamous cell carcinoma and its correlation with tumour angiogenesis

Contact Info

Product

Resources

About